TY - JOUR AU - Sobocki, P. AU - Jonsson, B. AU - Angst, J. AU - Rehnberg, C. PY - 2006 DA - 2006// TI - Cost of depression in Europe JO - J Ment Health Policy Econ VL - 9 ID - Sobocki2006 ER - TY - JOUR AU - Wittchen, H. U. AU - Jacobi, F. PY - 2005 DA - 2005// TI - Size and burden of mental disorders in Europe–a critical review and appraisal of 27 studies JO - Eur Neuropsychopharmacol VL - 15 UR - https://doi.org/10.1016/j.euroneuro.2005.04.012 DO - 10.1016/j.euroneuro.2005.04.012 ID - Wittchen2005 ER - TY - JOUR AU - Lepine, J. P. AU - Gastpar, M. AU - Mendlewicz, J. AU - Tylee, A. PY - 1997 DA - 1997// TI - Depression in the community: the first pan-European study DEPRES (depression research in European society) JO - Int Clin Psychopharmacol VL - 12 UR - https://doi.org/10.1097/00004850-199701000-00003 DO - 10.1097/00004850-199701000-00003 ID - Lepine1997 ER - TY - JOUR AU - Sonawalla, S. B. AU - Fava, M. PY - 2001 DA - 2001// TI - Severe depression: is there a best approach? JO - CNS Drugs VL - 15 UR - https://doi.org/10.2165/00023210-200115100-00003 DO - 10.2165/00023210-200115100-00003 ID - Sonawalla2001 ER - TY - JOUR AU - Sobocki, P. AU - Ekman, M. AU - Agren, H. AU - Runeson, B. AU - Jonsson, B. PY - 2006 DA - 2006// TI - The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression JO - Int J Clin Pract VL - 60 UR - https://doi.org/10.1111/j.1742-1241.2006.00997.x DO - 10.1111/j.1742-1241.2006.00997.x ID - Sobocki2006 ER - TY - BOOK AU - Friedman, E. AU - Anderson, I. M. PY - 2010 DA - 2010// TI - Managing depression in clinical practice PB - Springer CY - London UR - https://doi.org/10.1007/978-1-84996-465-4 DO - 10.1007/978-1-84996-465-4 ID - Friedman2010 ER - TY - JOUR AU - Nierenberg, A. A. AU - Ostacher, M. J. AU - Huffman, J. C. AU - Ametrano, R. M. AU - Fava, M. AU - Perlis, R. H. PY - 2008 DA - 2008// TI - A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder JO - J Occup Environ Med VL - 50 UR - https://doi.org/10.1097/JOM.0b013e31816b5034 DO - 10.1097/JOM.0b013e31816b5034 ID - Nierenberg2008 ER - TY - JOUR AU - Kent, J. M. PY - 2000 DA - 2000// TI - SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression JO - Lancet VL - 355 UR - https://doi.org/10.1016/S0140-6736(99)11381-3 DO - 10.1016/S0140-6736(99)11381-3 ID - Kent2000 ER - TY - JOUR AU - Blakely, R. D. PY - 2001 DA - 2001// TI - Physiological genomics of antidepressant targets: keeping the periphery in mind JO - J Neurosci VL - 21 ID - Blakely2001 ER - TY - JOUR AU - Pacher, P. AU - Kohegyi, E. AU - Kecskemeti, V. AU - Furst, S. PY - 2001 DA - 2001// TI - Current trends in the development of new antidepressants JO - Curr Med Chem VL - 8 UR - https://doi.org/10.2174/0929867013373796 DO - 10.2174/0929867013373796 ID - Pacher2001 ER - TY - JOUR AU - de Bodinat, C. AU - Guardiola-Lemaitre, B. AU - Mocaer, E. AU - Renard, P. AU - Munoz, C. AU - Millan, M. J. PY - 2010 DA - 2010// TI - Agomelatine, the first melatonergic antidepressant: discovery, characterization and development JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3274 DO - 10.1038/nrd3274 ID - de Bodinat2010 ER - TY - JOUR AU - Eser, D. AU - Baghai, T. C. AU - Moller, H. J. PY - 2009 DA - 2009// TI - Agomelatine: the evidence for its place in the treatment of depression JO - Core Evid VL - 4 UR - https://doi.org/10.2147/CE.S6005 DO - 10.2147/CE.S6005 ID - Eser2009 ER - TY - JOUR AU - Kennedy, S. H. AU - Rizvi, S. J. PY - 2010 DA - 2010// TI - Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness JO - CNS Drugs VL - 24 UR - https://doi.org/10.2165/11534420-000000000-00000 DO - 10.2165/11534420-000000000-00000 ID - Kennedy2010 ER - TY - BOOK AU - Briggs, A. AU - Claxton, K. AU - Sculpher, M. PY - 2006 DA - 2006// TI - Decision modelling for health economic evaluation PB - Oxford University Press Inc CY - New York ID - Briggs2006 ER - TY - JOUR AU - Barrett, B. AU - Byford, S. AU - Knapp, M. PY - 2005 DA - 2005// TI - Evidence of cost-effective treatments for depression: a systematic review JO - J Affect Disord VL - 84 UR - https://doi.org/10.1016/j.jad.2004.10.003 DO - 10.1016/j.jad.2004.10.003 ID - Barrett2005 ER - TY - JOUR AU - Sobocki, P. AU - Ekman, M. AU - Ovanfors, A. AU - Khandker, R. AU - Jonsson, B. PY - 2008 DA - 2008// TI - The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder JO - Int J Clin Pract VL - 62 UR - https://doi.org/10.1111/j.1742-1241.2008.01711.x DO - 10.1111/j.1742-1241.2008.01711.x ID - Sobocki2008 ER - TY - JOUR AU - Sobocki, P. AU - Ekman, M. AU - Agren, H. AU - Jonsson, B. AU - Rehnberg, C. PY - 2006 DA - 2006// TI - Model to assess the cost-effectiveness of new treatments for depression JO - Int J Technol Assess Health Care VL - 22 UR - https://doi.org/10.1017/S0266462306051397 DO - 10.1017/S0266462306051397 ID - Sobocki2006 ER - TY - JOUR AU - Maniadakis, N. AU - Kaitelidou, D. AU - Siskou, O. AU - Spinthouri, M. AU - Liaropoulos, L. AU - Fragoulakis, B. AU - Hatzikou, M. AU - Alexopoulosi, D. PY - 2005 DA - 2005// TI - Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece JO - Hellenic J Cardiol VL - 46 ID - Maniadakis2005 ER - TY - JOUR PY - 2000 DA - 2000// TI - Practice guideline for the treatment of patients with major depressive disorder (revision) JO - Am J Psychiatry VL - 157 UR - https://doi.org/10.1176/ajp.157.1.1 DO - 10.1176/ajp.157.1.1 ID - ref19 ER - TY - JOUR AU - Lemoine, P. AU - Guilleminault, C. AU - Alvarez, E. PY - 2007 DA - 2007// TI - Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine JO - J Clin Psychiatry VL - 68 UR - https://doi.org/10.4088/JCP.v68n1112 DO - 10.4088/JCP.v68n1112 ID - Lemoine2007 ER - TY - JOUR AU - Kasper, S. AU - Hajak, G. AU - Wulff, K. AU - Hoogendijk, W. J. AU - Montejo, A. L. AU - Smeraldi, E. AU - Rybakowski, J. K. AU - Quera-Salva, M. A. AU - Wirz-Justice, A. M. AU - Picarel-Blanchot, F. AU - Bayle, F. J. PY - 2010 DA - 2010// TI - Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline JO - J Clin Psychiatry VL - 71 UR - https://doi.org/10.4088/JCP.09m05347blu DO - 10.4088/JCP.09m05347blu ID - Kasper2010 ER - TY - JOUR AU - Hale, A. AU - Corral, R. M. AU - Mencacci, C. AU - Ruiz, J. S. AU - Severo, C. A. AU - Gentil, V. PY - 2010 DA - 2010// TI - Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study JO - Int Clin Psychopharmacol VL - 25 UR - https://doi.org/10.1097/YIC.0b013e32833a86aa DO - 10.1097/YIC.0b013e32833a86aa ID - Hale2010 ER - TY - JOUR AU - Quera-Salva, M. A. AU - Hajak, G. AU - Philip, P. AU - Montplaisir, J. AU - Keufer-Le Gall, S. AU - Laredo, J. AU - Guilleminault, C. PY - 2011 DA - 2011// TI - Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients JO - Int Clin Psychopharmacol VL - 26 UR - https://doi.org/10.1097/YIC.0b013e328349b117 DO - 10.1097/YIC.0b013e328349b117 ID - Quera-Salva2011 ER - TY - JOUR AU - Bielski, R. J. AU - Ventura, D. AU - Chang, C. C. PY - 2004 DA - 2004// TI - A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder JO - J Clin Psychiatry VL - 65 UR - https://doi.org/10.4088/JCP.v65n0906 DO - 10.4088/JCP.v65n0906 ID - Bielski2004 ER - TY - JOUR AU - Angst, J. AU - Gamma, A. AU - Sellaro, R. AU - Lavori, P. W. AU - Zhang, H. PY - 2003 DA - 2003// TI - Recurrence of bipolar disorders and major depression. A life-long perspective JO - Eur Arch Psychiatry Clin Neurosci VL - 253 UR - https://doi.org/10.1007/s00406-003-0437-2 DO - 10.1007/s00406-003-0437-2 ID - Angst2003 ER - TY - JOUR AU - Harris, E. C. AU - Barraclough, B. PY - 1997 DA - 1997// TI - Suicide as an outcome for mental disorders. A meta-analysis JO - Br J Psychiatry VL - 170 UR - https://doi.org/10.1192/bjp.170.3.205 DO - 10.1192/bjp.170.3.205 ID - Harris1997 ER - TY - JOUR AU - Montgomery, S. A. AU - Kennedy, S. H. AU - Burrows, G. D. AU - Lejoyeux, M. AU - Hindmarch, I. PY - 2004 DA - 2004// TI - Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study JO - Int Clin Psychopharmacol VL - 19 UR - https://doi.org/10.1097/01.yic.0000137184.64610.c8 DO - 10.1097/01.yic.0000137184.64610.c8 ID - Montgomery2004 ER - TY - CHAP AU - Rouillon, F. PY - 2007 DA - 2007// TI - A study to determine the maintenance of efficacy of agomelatine (25 mg or 50 mg) in order to prevent relapses in out-patients with major depressive disorder BT - A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period PB - Créteil CY - France ID - Rouillon2007 ER - TY - JOUR AU - Kennedy, S. H. AU - Rizvi, S. AU - Fulton, K. AU - Rasmussen, J. PY - 2008 DA - 2008// TI - A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR JO - J Clin Psychopharmacol VL - 28 UR - https://doi.org/10.1097/JCP.0b013e318172b48c DO - 10.1097/JCP.0b013e318172b48c ID - Kennedy2008 ER - TY - JOUR AU - Baldwin, D. S. AU - Montgomery, S. A. AU - Nil, R. AU - Lader, M. PY - 2007 DA - 2007// TI - Discontinuation symptoms in depression and anxiety disorders JO - Int J Neuropsychopharmacol VL - 10 UR - https://doi.org/10.1017/S1461145705006358 DO - 10.1017/S1461145705006358 ID - Baldwin2007 ER - TY - JOUR AU - Goodwin, G. M. AU - Emsley, R. AU - Rembry, S. AU - Rouillon, F. PY - 2009 DA - 2009// TI - Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial JO - J Clin Psychiatry VL - 70 UR - https://doi.org/10.4088/JCP.08m04548 DO - 10.4088/JCP.08m04548 ID - Goodwin2009 ER - TY - JOUR AU - Sobocki, P. AU - Ekman, M. AU - Agren, H. AU - Krakau, I. AU - Runeson, B. AU - Martensson, B. AU - Jonsson, B. PY - 2007 DA - 2007// TI - Health-related quality of life measured with EQ-5D in patients treated for depression in primary care JO - Value Health VL - 10 UR - https://doi.org/10.1111/j.1524-4733.2006.00162.x DO - 10.1111/j.1524-4733.2006.00162.x ID - Sobocki2007 ER - TY - JOUR AU - Sullivan, P. W. AU - Valuck, R. AU - Saseen, J. AU - MacFall, H. M. PY - 2004 DA - 2004// TI - A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions JO - CNS Drugs VL - 18 UR - https://doi.org/10.2165/00023210-200418130-00006 DO - 10.2165/00023210-200418130-00006 ID - Sullivan2004 ER - TY - JOUR AU - Botteman, M. F. AU - Ozminkowski, R. J. AU - Wang, S. AU - Pashos, C. L. AU - Schaefer, K. AU - Foley, D. J. PY - 2007 DA - 2007// TI - Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model JO - CNS Drugs VL - 21 UR - https://doi.org/10.2165/00023210-200721040-00005 DO - 10.2165/00023210-200721040-00005 ID - Botteman2007 ER - TY - CHAP PY - 2012 DA - 2012// BT - EPAR summary for the public ID - ref35 ER - TY - CHAP PY - 2012 DA - 2012// BT - Drug Price Bulletin ID - ref36 ER - TY - JOUR AU - Eichler, H. G. AU - Kong, S. X. AU - Gerth, W. C. AU - Mavros, P. AU - Jonsson, B. PY - 2004 DA - 2004// TI - Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? JO - Value Health VL - 7 UR - https://doi.org/10.1111/j.1524-4733.2004.75003.x DO - 10.1111/j.1524-4733.2004.75003.x ID - Eichler2004 ER - TY - JOUR AU - Devlin, N. AU - Parkin, D. PY - 2004 DA - 2004// TI - Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis JO - Health Econ VL - 13 UR - https://doi.org/10.1002/hec.864 DO - 10.1002/hec.864 ID - Devlin2004 ER - TY - CHAP PY - 2001 DA - 2001// TI - Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health BT - Book WHO commission on macroeconomics and health: macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health PB - Switzerland CY - Geneva ID - ref39 ER - TY - JOUR AU - Remak, E. AU - Charbonneau, C. AU - Negrier, S. AU - Kim, S. T. AU - Motzer, R. J. PY - 2008 DA - 2008// TI - Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.2662 DO - 10.1200/JCO.2007.13.2662 ID - Remak2008 ER - TY - JOUR AU - Lothgren, M. AU - Zethraeus, N. PY - 2000 DA - 2000// TI - Definition, interpretation and calculation of cost-effectiveness acceptability curves JO - Health Econ VL - 9 UR - https://doi.org/3.0.CO;2-V DO - 3.0.CO;2-V ID - Lothgren2000 ER - TY - JOUR AU - Himmerich, H. AU - Wranik, D. W. PY - 2012 DA - 2012// TI - Choice of treatment with antidepressants: influencing factors JO - Curr Pharm Des VL - 18 UR - https://doi.org/10.2174/138161212803523653 DO - 10.2174/138161212803523653 ID - Himmerich2012 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/13/173/prepub UR - http://www.biomedcentral.com/1472-6963/13/173/prepub ID - ref43 ER -